NasdaqGS:AMGNBiotechs
Evaluating Amgen (AMGN) After Barclays Coverage And Strong Q4 2025 Portfolio Momentum
What Barclays’ Coverage Means For Amgen Stock
Barclays’ new coverage of Amgen (AMGN), paired with the company’s recent Q4 2025 earnings updates, has pushed the stock back into focus for investors watching large cap biotech names.
The coverage comes as Amgen highlights portfolio momentum, with 14 products each generating over US$1b in annual sales and double digit growth in therapies such as Repatha, EVENITY, and TEZSPIRE.
See our latest analysis for Amgen.
Against this backdrop, Amgen’s share...